High Volume Plasmapheresis for Refractory Hepatic Encephalopathy in Liver Intensive Care Unit.
Status:
Withdrawn
Trial end date:
2019-04-15
Target enrollment:
Participant gender:
Summary
Study Design- Randomized Controlled trial Duration of enrolment-Feb-2016 to December 2017
Sample size-120 patients Methodology We will include consecutive with advanced hepatic
encephalopathy not responding to treatment of precipitants and on treatment with Lactulose
and Rifaximin for 48 hours .
Two groups will be divided. One arm -Lactulose and Rifaximin will be continued Second Arm -
Plasmapheresis will be added to the standard medical care therapy.(Maximum of 3 sessions once
in 24 hours/or alternate days with an follow up for 5 days)